RANTES: A genetic risk marker for multiple sclerosis

Multiple Sclerosis

Volumn 10, Issue 5, 2004, Pages 536-539

  Gade Andavolu, Radhika ^a   Comings, David E ^b   McMurray, James ^b   Vuthoori, Ravi K ^a   Tourtellote, Wallace W ^c   Nagra, Rashed M ^c   Cone, Lawrence A ^a  

^a EISENHOWER MEDICAL CENTER   (United States)

^b Carlsbad Science Foundation   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Central nervous system; Chemokines; Cytokines; Multiple sclerosis; RANTES

Indexed keywords

ALANINE; CYSTEINE; GLYCINE; RANTES;

ADULT; AGED; ALLELE; ARTICLE; AUTOPSY; BRAIN TISSUE; CAUCASIAN; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SCREENING; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; ONSET AGE; PROMOTER REGION; SURVIVAL;

ADULT; AGED; FEMALE; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); RANTES; RISK FACTORS;

EID: 4444343941     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/1352458504ms1080oa     Document Type: Article

References (25)

1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000; 343: 938-52.
2. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996; 46: 907-11.
3. Sorensen TL, Tani M, Jensen J, Pierce V, Lucchinetti C, Folcik VA et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest 1999; 103: 807-15.
4. Sun D, Tani M, Newman TA, Krivacic K, Phillips M, Chernosky A et al. Role of chemokines, neuronal projections, and the blood brain barrier in the enhancement of cerebral EAE following focal brain damage. J Neuropathol Exp Neurol 2000; 59: 1031-43.
5. Simpson JE, Newcombe J, Cuzner ML, Woodroofe MN. Expression of monocyte chem-attractant protein-1 and other beta-chemokines by resident glia and inflammatory cells in multiple sclerosis lesions. J Neuroimmunol 1998; 84: 238-49.
6. Palma JP, Kim BS. Induction of selected chemokines in glial cells infected with Theiler's virus. J Neuroimmunol 2001; 117: 166-70.
7. Baranzini SE, Elfstrom C, Chang SY, Butunoi C, Murray R, Higuchi R et al. Transcriptional analysis of multiple sclerosis brain lesions reveal a complex pattern of cytokine expression. J Immunol 2000; 16: 6576-82.
8. Hvas J, McLean C, Justesen J, Kannourakis G, Steinman L, Oksenberg JR et al. Perivascular T cells express pro-inflammatory chemokine RANTES mRNA in multiple sclerosis lesions. Scand J Immunol 1997; 46: 195-203.
9. Barnes DA, Huston M, Holmes R, Benveniste EN, Yong VW, Scholz P et al. Induction of RANTES expression by astrocytes and astrocytoma cell lines. J Neuroimmunol 1996; 71: 207-14.
10. Li QQ, Bever CT, Burt DR, Judge SI, Trisler GD. Induction of RANTES chemokine expression in human astrocytic cells is dependent upon activation of NF-kappa B transcription factor. Int J Mol Med 2001; 7: 427-33.
11. Li QQ, Bever CT. Comparison of RANTES chemokine induction by Th1 cytokines in human astoglial cell lines. Int J Mol Med 2001; 8: 95-101.
12. Kivisakk P, Teleshova N, Ozenci V, Huang Y, Matusevicius D, Fredrikson S et al. No evidence for elevated numbers of mononuclear cells expressing MCP-1 and RANTES mRNA in blood and CSF in multiple sclerosis. J Neuroimmunol 1998; 91: 108-12.
13. Iarlori C, Reale M, Lugaresi A, De Luca G, Bonanni L, Di Iorio A et al. RANTES production and expression is reduced in relapsing-remitting multiple sclerosis patients treated with interferon-beta-1b. J Neuroimmunol 2000; 107: 100-107.
14. Sindern E, Niederkinkhaus Y, Henschel M, Ossege LM, Patzold T, Malin JP. Differential release of beta-chemokines in serum and CSF of patients with relapsing-remitting multiple sclerosis. Acta Neurol Scand 2001; 104: 88-91.
15. Zang YC, Halder JB, Samanta AK, Hong J, Rivera VM, Zhang JZ. Regulation of chemokine receptor CCR5 and production of RANTES and MIP-1alpha by interferon-beta. J Neuroimmunol 2001; 112: 174-80.
16. Li QQ, Bever CT. Th1 cytokines stimulate RANTES chemokine secretion by human astroglial cells depending on de novo transcription. Neurochem Res 2001; 26: 125-33.
17. Gade-Andavolu R, Comings DE, MacMurray J, RostamKhani M, Tourttelotte W, Cone LA. CCR5 delta 32 mutation predicts survival in patients with multiple sclerosis. Genet Med 2004; 6: 126-31.
18. Donlon TA, Krensky AM, Wallace,MR, Collins FS, Lovett M, Clayberger C. Localization of a human T cell specific gene, RANTES (D17s136E) to chromosome 17q11.2-q12. Genomics 1990; 6: 548-53.
19. Liu H, Chao D, Nakayama EE, Taguchi H, Goto M, Xin X et al. Polymorphism in RANTES chemokine promoter affects HIV-1 disease progression. Proc Natl Acad Sci USA 1999; 96: 4581-85.
20. McDermott DH, Beecroft MJ, Kleeberger CA, Al-Sharif FM, Ollier WE, Zimmerman PA et al. Chemokine RANTES promoter polymorphism affects risk of both HIV infection and disease progression in the Multi-center AIDS Cohort Study. AIDS 2000; 14: 2671-78.
21. Gonzalez E, Dhanda R, Bamshad M, Mummidi S, Geevarghese R, Catano G et al. Global survey of genetic variation in CCR5, RANTES, and MIP-1alpha: impact on the epidemiology of the HIV-1 pandemic. Proc Natl Acad Sci USA 2001; 98: 5199-204.
22. Hajeer AH, Al-Sharif F, Ollier WE. A polymorphism at position -403 in the human RANTES promoter. Eur J Immunogenet 1999; 26: 373-74.
23. Al-Sharif FM, Ollier WE, Hajeer AH. A rare polymorphism at position -28 in the human RANTES promoter. Eur J Immunogenet 1999; 5: 373-74.
24. Midgard R, Albrektsen G, Riise T, Kvale G, Nyland H. Prognostic factors for survival in multiple sclerosis: a longitudinal, population based study in More and Romsdal, Norway. J Neurol Neurosurg Psychiatry 1995; 58: 417-21.
25. Comings DE, Gonzalez NS, Cheng Li S-C, MacMurray J. A 'line item' approach to the identification of genes involved in polygenic behavioral disorders: the adrenergic 2A (ADRA2A) gene. Am J Med Genet (Neurospychiatric Genetics) 2003; 118B: 110-14.